We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

77 hedge funds and large institutions have $19M invested in Galectin Therapeutics in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $321K | Put options by funds: $208K

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

0.71% less ownership

Funds ownership: 17.69% → 16.98% (-0.71%)

1% less funds holding

Funds holding: 78 → 77 (-1)

19% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 21

34% less capital invested

Capital invested by funds: $28.8M → $19M (-$9.81M)

Holders
77
Holders Change
-1
Holders Change %
-1.28%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
17
Reduced
21
Closed
8
Calls
$321K
Puts
$208K
Net Calls
+$113K
Net Calls Change
+$525K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$98.6K
2
JP Morgan Chase
JP Morgan Chase
New York
+$66.8K
3
Northern Trust
Northern Trust
Illinois
+$65K
4
N
Nuveen
North Carolina
+$55.4K
5
Two Sigma Investments
Two Sigma Investments
New York
+$41.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$263K
2
CCB
Cutter & Co Brokerage
Missouri
-$255K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$219K
4
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$174K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$122K
Name Holding Trade Value Shares
Change 		Change in
Stake
RJA
26
Raymond James & Associates
Florida
$54K – – –
LPL Financial
27
LPL Financial
California
$52K – – –
HS
28
HighVista Strategies
Massachusetts
$50K -$11.9K -4,900 -16%
UBS Group
29
UBS Group
Switzerland
$49K -$64K -26,310 -51%
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$48K – – –
AIG
31
American International Group
New York
$46K -$3.33K -1,370 -5%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$46K – – –
VOYA Investment Management
33
VOYA Investment Management
Georgia
$45K – – –
WS
34
Wedbush Securities
California
$40K -$2.43K -1,000 -5%
Renaissance Technologies
35
Renaissance Technologies
New York
$39K -$46.2K -19,000 -49%
IWM
36
IHT Wealth Management
Illinois
$36K – – –
Goldman Sachs
37
Goldman Sachs
New York
$33K -$37.5K -15,401 -48%
IGGA
38
Iron Gate Global Advisors
Utah
$33K – – –
Two Sigma Investments
39
Two Sigma Investments
New York
$33K +$41.2K +16,932 New
CAN
40
Cetera Advisor Networks
California
$32K – – –
CF
41
Centaurus Financial
California
$30K -$151 -62 -0.4%
Deutsche Bank
42
Deutsche Bank
Germany
$28K -$18.2K -7,464 -35%
Victory Capital Management
43
Victory Capital Management
Texas
$28K +$36K +14,782 New
Barclays
44
Barclays
United Kingdom
$27K -$64.9K -26,678 -67%
WANY
45
Wealthspire Advisors (New York)
New York
$27K – – –
JA
46
JOYN Advisors
Georgia
$25K – – –
AIC
47
Ameritas Investment Company
Nebraska
$25K +$6.08K +2,500 +23%
SG Americas Securities
48
SG Americas Securities
New York
$25K +$31.3K +12,876 New
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$24.4K +$16.2K +6,656 +115%
Citigroup
50
Citigroup
New York
$24K +$10.1K +4,166 +52%
1
2
3 4

GALT Hedge Fund Activity: Q1 2020 in Review

77 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2020, worth a combined $19M — down 34% from $28.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GALT positions and 8 closed out — a net gain of 2 holders — while 17 added to existing stakes and 21 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $98.6K. The largest seller was Morgan Stanley, cutting an estimated $263K.

  • 77 institutional investors held Galectin Therapeutics (GALT) as of Q1 2020, down from 78 in Q4 2019.
  • Funds reported $19M of Galectin Therapeutics stock for Q1 2020, down 34% quarter-over-quarter.
  • 10 funds opened new Galectin Therapeutics positions in Q1 2020 and 8 closed out, a net change of +2 holders.
  • The largest Galectin Therapeutics buyer in Q1 2020 was Citadel Advisors, an estimated $98.6K added.
  • The largest Galectin Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $263K sold.

Based on aggregated 13F filings for Q1 2020.